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List of abbreviations 
 
Δ9-THC  =  Δ9-tetrahydrocannabinol 
2-AG  =  2-arachidonoylglycerol 
2-OG  =  2-oleoylglycerol 
AA  =  arachidonic acid  
ABHD-6, ABHD-12  =  α-β-hydrolase domain 6,12  
ACN  =  acetonitrile 
ADHP  =  10-acetyl-3,7-dihydroxyphenoxazine 
AEA  =  N-arachidonoylethanolamide 
BCP  =  β - caryophyllene 
BSA  =  bovine serum albumin 
CAB  =  COX activity buffer 
CB1r, CB2r  =  cannabinoid receptor 1, 2 
CCl3  =  chloroform 
COX-2  =  cyclooxygenase 2 
cpm  =  counts per minute 
CTRL  =  control 
DMSO  = dimethyl sulfoxide 
ECs  =  endocannabinoid system 
EtOH  =  ethanol  
FA  =  formic acid 
FAAH  =  fatty acid amide hydrolase 
GC-MS  =  gas chromatography–mass spectrometry 
Heme  =  hematin 
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IS  =  internal standard 
LC-MS/MS  =  Liquid chromatography–mass spectrometry/ mass spectrometry 
LEA  =  Linoleoylethanolamide 
MAGL  =  mono acyl glycerol lipase 
MeOH  =  methanol 
NADA  =  N-arachidonoyl-dopamine 
NE  =  noladin ether 
OEA  =  Oleoylethanolaminde 
PBS =  Phosphate buffered saline 
PEA  =  palmitoyl ethanolamide 
PGE2  =  Prostaglandin E2 
PGD2  =  Prostaglandin D2 
rpm  =  revolutions per minute 
Veh  =  vehicle 
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1. General Introduction 
The endocannabinoid system (ECs) was discovered quite recently, in the early 
1990s, and since then was widely studied. The Δ9-tetrahydrocannabinol (THC) is the 
main psychoactive component of Cannabis sativa and like the others endogenous 
ligands was unknown for many years. Only later, chemistry, metabolism, 
biochemistry, and pharmacology of them where investigated. The endocannabinoid 
system is composed by different parts: the two main cannabinoid receptors 1 and 2 
(CB1 and CB2), the endogenous ligands 2-arachidonylglycerol (2-AG) and N-
arachidonoylethanolamide  (Anandamide, AEA) which are the most potent, few 
other ligands and the enzyme involved in the biosynthesis and metabolism of them 
(Pertwee 2015) (Figure 1.1). This system seems to be involved in an ever-increasing 
number of pathological conditions and this is the reason why is so investigated. 
 
Figure 1.1 Scheme of the ECS (Chicca A. artwork) 
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1.1. The ECs 
The two receptors CB1 and CB2 are G protein-coupled receptors and their 
correlation with the ECS as their cloning comes out in the 1990s (Matsuda LA et al. 
1990; Munro S, et al. 1993). The CB1 receptors are expressed in the central nervous 
system (CNS) and in the periphery as the CB2 (Mackie K et al 2006) but these are 
also located on blood cells and immune tissues (Di Marzo et al. 2004). The two best-
studied endocannabinoids are AEA and 2-AG and like the other endocannabinoids 
identified, they are derivatives (amides, esters and even ethers) of long- chain 
polyunsaturated fatty acids, specifically arachidonic acid, and exhibit varying 
selectivity for the two cannabinoid receptors. AEA is biosynthesized by N-
Acylphosphatidyl- Ethanolamine-Selective Phospholipase D (NAPE-PLD), whereas 2-
AG is produced by phospholipase C (PLC) and diacylglycerol lipase (DAGL) (Di Marzo 
et al. 2004). AEA was the first endogenous cannabinoid identified (Devane et al. 
1992) and behaves as a partial agonist at both cannabinoid CB1 and CB2 receptors 
(Pertwee et al. 2010). It can also bind to the transient receptor potential vanilloid 1 
(TRPV1)(Zygmunt et al. 1999) and the peroxisome proliferator-activated receptor 
(PPAR) family (O’Sullivan 2007). 2-AG can bind both CB1 and CB2 receptors and 
behaves as a full agonist (Sugiura 2009). To have an idea of the amount of these two 
endocannabinoids in the brain, was detected that the level of AEA in the mice is 
around 8.5 ± 0.9 pmol/g while 2-AG is around 1.9 ± 0.3 nmol/g (Han et al. 2013). 
They are both synthesized on demand and when they bind to the CB1r or CB2r  there 
is an inhibition of adenylyl cyclase and an activation of mitogen-activated protein 
kinase by signaling through Gi/o proteins. This ability is frequently exploited in two 
widely used in vitro bioassays: the [35S]GTPγS binding assay and the cAMP assay 
(Pertwee et al. 2010). After their binding to the receptors, the endocannabinoids 
are immediately removed from the extracellular place by uptake and degraded. The 
endocannabinoids are retrograde messengers: when they travel from the 
postsynaptic element to the presynaptic cells they can inhibit their own release 
(Alger 2002).  
Others endocannabinoids that were discovered are: 2-Arachidonoy-glyceryl ether 
(2-AGE, noladin ether, NE), Virodhamine which is the ester of arachidonic acid and 
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N-arachidonoyl-dopamine (NADA). Noladin ether binds selectively to CB1r vs. CB2r 
and functionally activates the CB1r (Fezza et al. 2002) while the virodhamine act as a 
full agonist for CB2r , has antagonist activity at the CB1r and a weak inhibitor of AEA 
uptake (Porter 2002). For what concern the NADA we can say that has an effect on 
both CB1 (Bisogno et al. 2000) and VR1 receptors (Huang et al. 2002). Finally, are 
worthy to be mention  a group of compounds defined as endocannabinoid-like: 
Palmitoylethanolamide (PEA), Oleoyethanolamide (OEA) and Linoleoylethanolamide 
(LEA). These fatty acid ethanolamides exert their cannabimimetic effects by acting 
as “entourage molecules” (see Figure 1.2). 
 
Figure 1.2 Chemical stuctures of endocannabinoids. 
The degradation of the endocannabinoids occurs through two different 
mechanisms: one hydrolytic and the other oxidative. The main enzymes involve are 
Fatty Acid Amide Hydrolase (FAAH), Mono Acyl Glycerol lipase (MAGL), α/β 
Hydrolases (ABHD-6 and ABHD-12) and Cyclooxygenase type II (COX-2). The 
endocannabinoids balance is governed also by the transport across the cell 
membrane through the endocannabinoid membrane transporter (EMT). 
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1.1.1. Fatty Acid Amide Hydrolase (FAAH) 
AEA is mainly hydrolyzed by FAAH (Cravatt et al. 1996)(Giang & Cravatt 1997) which 
is a member of the serine hydrolase family of enzymes. This enzyme is an integral 
membrane hydrolase with a single N-terminal transmembrane domain that has 
esterase and amidase activity (Patricelli & Cravatt 1999). For the catalytic effect 
three residues are important: Ser241, Lys142 and Ser217. The Ser241 is the 
nucleophile that attack the carbonyl group of the substrate (with the development 
of an acyl-enzyme intermediate), the Lys142 appears to play an important role in 
the acid-catalyzed protonation of the substrate-leaving group, while the Ser217 
seems to help as the Lys142 the activity of the Ser241 (McKinney & Cravatt 2003). 
The reaction is stopped by a water-induced hydrolysis of the acyl intermediate and 
the consecutive regeneration of the enzyme with the release of the free fatty acid. 
FAAH is also involved in the hydrolysis of 2-AG (Di Marzo & Deutsch 1998).It has 
been shown that inhibition of FAAH and the related increase of AEA levels in the 
tissues lead to beneficial effect. One of the most  used selective inhibitor of its 
activity is KDS-4103 (URB597) with a median inhibitory concentrations (IC50) of 5 nM 
in rat brain membranes and 3 nM in human liver microsomes (Piomelli et al. 2006) 
(Figure 1.3). Anxiolytic effects (Scherma et al. 2012) and analgesia in inflammatory 
pain states (Jayamanne et al. 2006) were demonstrated for that compound which 
does not activate, as other FAAH inhibitors, the CB1r with the consequent classical 
central side effects such as catalepsy, hypothermia, hypomotility and reinforcing 
effect (Justinova et al. 2009). 
 
 
Figure 1.3 Chemical structure of URB597. 
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1.1.2. Mono Acyl Glycerol lipase (MAGL) 
MAGL, that converts monoacylgylcerols to fatty acid and glycerol, is another 
member of the serine hydrolase family. Is mainly responsible of the degradation of 
the 2-AG and is located in the areas of the brain were also CB1 receptors are very 
high (for example hippocampus, cerebellum, anterodorsal nucleus of the thalamus, 
and cortex) (Dinh et al. 2002). MAGL is a soluble enzyme that associates with 
membranes in a peripheral manner with a cytoplasmatic orientation. All brain 2- AG 
hydrolase activity (> 98%) can be accounted for by three enzymes – MAGL (~85% of 
total), ABHD12 (~9% of total), and ABHD6 (~4% of total) with the remaining ~2% 
activity presumably being performed by FAAH and/ or other enzymes (Blankman et 
al. 2009). The catalytic triad, made up of residues Ser122, Asp239 and His269, is the 
typical one of the serine hydrolase family and the cap domain allows interaction 
with membranes and the creation of a mix hydrophobic/hydrophilic environment 
optimal for the accommodation of monoacylglycerols in the catalytic site (Labar et 
al. 2010). Inside the catalytic site, the Ser122 of the catalytic triad, is the target of 
many recent carbamate-based covalent inhibitors as JZL184 (Figure 1.4). This is an 
inhibitor that inactivate serine hydrolases by irreversible (or slowly reversible) 
covalent modification (carbamoylation) of the catalytic serine nucleophile (Long et 
al. 2009) and exhibit a high selectivity over FAAH. JZL184 significantly inhibits 
inflammatory pain ( Ghosh et al . 2012) and attenuates pain in a neuroinflammatory 
disease model (Kinsey et al. 2009). 
 
 
 
 
Figure 1.4 Chemical structure of JZL 184 
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1.1.3. α/β Hydrolases (ABHD-6 and ABHD-12) 
Also these two enzymes belong to the serine hydrolase family that are involved in 2-
AG hydrolysis. They are two integral membrane proteins with the catalytic triad 
serine-aspartic acid-histidine (Savinainen et al. 2012). ABHD-12 has its active site 
oriented toward the luminal/ extracellular compartments of the cell, while ABHD-6 
faces the cytoplasm (Blankman et al. 2009). At present, only a limited number of 
ABHD-6 inhibitors are described like the potent and selective WWL70 (IC50= 70 nM) 
that  was discovered by Cravatt’s group and also has a carbamate scaffold (Li et al. 
2007). As already said talking about MAGL activity, ABHD-12 has a minor role in 2-
AG hydrolysis and as ABHD-6 it has only few inhibitors known. One of these is THL 
(or Orlistat), which is relatively potent (IC50=190nM) but not selective (in fact is able 
to inhibit also ABHD-6)(Navia-Paldanius et al. 2012) (Figure 1.5). 
 
 
Figure 1.5 Chemical structure of WWL70 and THL. 
 
1.1.4. Cyclooxygenase type II (COX-2) 
Cyclooxygenase II (COX-2) is an enzyme that is usually responsible for the 
conversion of arachidonic acid (AA) to prostaglandins (PGs). This enzyme is also able 
to metabolize the endocannabinoids through an oxidative pathway: 2-AG and AEA, 
generates respectively prostaglandin glycerol esters (PG-G) and ethanolamides (PG-
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EA). In cellular systems, the major COX-2 products, that come from 
endocannabinoid derived oxidation of PGH2-G and PGH2-EA, are the glycerol esters 
and ethanolamides PGE2, PGD2, and PGF2α (Kozak et al. 2002). The oxidation of 
both the endocannabinoids is not possible by COX-1 but they can be also degraded 
by lipoxygenases (LOXs) as well as cytochrome P450 enzymes to produce the 
corresponding hydroxy- (in the case of lipoxygenases) and epoxy- (in the case of 
cytochrome P450 monooxidases) derivatives. The metabolites that come out from 
the oxidative conversion mechanisms do not necessarily represent inactivation 
pathways for endocannabinoids, but may mimic or modulate the endocannabinoids 
or even display alternative pharmacology (Urquhart et al. 2015) (Figure 1.6). 
 
Figure 1.6 Oxidative metabolism of endocannabinoids (Brown et al. 2013). 
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1.1.5. Endocannabinoid membrane transport (EMT) 
The mechanisms of endocannabinoid membrane transport are not completely 
understood. When the endocannabinoids 2-AG and AEA complete their activity, 
they are quickly removed from the extracellular space (uptake process) and 
metabolized. A study carried out by Di Marzo et al. , suggested that AEA uptake was 
a carrier-mediated process. This process is coupled to its metabolism by FAAH, but 
they are two distinct mechanisms (Deutsch et al. 2001). There are other models for 
AEA uptake as a simple cellular diffusion stopped by FAAH hydrolysys (Glaser et al. 
2003)(Kaczocha et al. 2006) or a carrier-mediated caveolae-related endocytotic 
process (McFarland et al. 2004). Surprisingly little is known about 2-AG uptake 
mechanism, even if is one of the major endocannabinoids. Chicca et al. suggested 
that a putative endocannabinoid cell membrane transporter (EMT)(it has not yet 
been identified) controls the cellular trafficking of both AEA and 2-AG and their 
metabolism (Chicca et al. 2012). 
 
 
1.1. β-caryophyllene  
The sesquiterpene (E)-β-caryophyllene (BCP) is a volatile aromatic compound that is 
widely present in essential oils of many different spices and food plants, such as 
cinnamon, oregano, black pepper, basil and cloves, but is also the major component 
(up to 35%) in the essential oil of Cannabis sativa L. Usually in nature is found with a 
small quantity of its isomer (Z)-β-caryophyllene ((Z)-BCP or isocaryophyllene) and α-
humulene (formerly α-caryophyllene). Is it also possible to find in that mixture the 
product of its oxidation, the BCP oxide (Figure 1.7).  
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Figure 1.7 Chemical structures of the bicyclic sesquiterpenes (E)-β-caryophyllene, (Z)-β-caryophyllene, 
caryophyllene oxide, and α-caryophyllene. (Gertsch et al. 2008) 
It has been shown that BCP selectively binds to CB2 receptor (Ki = 155 ± 4 nM) and 
behaves as a full agonist (Gertsch et al. 2008). BCP is also able to markedly 
attenuate the cisplatin-induced decline in kidney function in mice treated with 
10mg/Kg of compound  and ameliorate the observed histological damage (which 
are effects CB2 receptors mediated) (Bèla Horvàth et al. 2012). Endocannabinoids 
and endocannabinoid-like molecules acting through the CB2r have been reported to 
affect a large number of pathological conditions ranging from cardiovascular, 
gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, auto-
immune, lung disorders to pain and cancer (Pacher & Mechoulam 2011).  Orally 
administered BCP  produces strong anti-inflammatory and analgesic effects in wild-
type mice but not in CB2r knock-out mice (Gertsch et al. 2008) and exhibits both 
preventive and therapeutic effects in Dextran Sulfate Sodium-induced colitis in mice 
associated with activation of CB2 and PPARγ receptors (Bento et al. 2011). Related 
with the activation of CB2 and PPARγ receptors, there are evidences that BCP orally 
given prevent cognitive impairment in APP/PS1 mice, reduce β-amyloid burden 
in both the hippocampus and the cerebral cortex and in the cerebral cortex 
reduce astrogliosis and microglia activation as well as the levels of COX-2 
protein and the mRNA levels of the pro-inflammatory cytokines tumor necrosis 
factor-α and interleukin-1β, emerging as an attractive molecule for the 
development of new drugs with therapeutic potential for the treatment of 
Alzheimer's disease (AD) (Cheng et al. 2014). Another study shows that BCP (50 
mg/kg) given systemically is effective in producing a significant anxiolytic- and 
antidepressant-like effects in most widely-used predictive animal models of 
15 
 
anxiolytic (elevated plus maze (EPM), open field (OF), and marble burying 
test(MBT)) and antidepressant activity (novelty-suppressed feeding (NSF), tail 
suspension test (TST), and forced swim tests (FST)). The study also demonstrates 
that the anxiolytic and antidepressant actions of BCP are mediated through CB2r 
(Bahi et al. 2014). Interestingly BCP has also an effect on the voluntary alcohol 
intake in mice and dose-dependently decreased alcohol consumption and 
preference (Al Mansouri et al. 2014). 
For the CB2r binding, BCP docks into the hydrophobic cavity and the binding appears 
to be facilitated by - stacking interactions with residues F117 (4.0 Å) and W258 
(4.6 Å) (Gertsch et al. 2008)(Figure 1.8). 
 
Figure 1.8 Model of the putative interaction of (E)-BCP with the CB2 receptor. Model of the putative interaction 
of (E)-BCP with the CB2 receptor(Gertsch et al. 2008). 
Changes on this element were detrimental for activity, while it has been published 
that ring-opening cross metathesis of BCP with ethyl acrylate, followed by amide 
functionalization, generated a series of new monocyclic amides (propylamide, 2-
propenylamide and 2-chloroethylamide) that not only retained the CB2r functional 
agonism of BCP, but also reversibly inhibited fatty acid amide hydrolase (FAAH) 
without affecting monoacylglycerol lipase (MAGL) and α,β hydrolases-6 and -12. 
Intriguingly, further modification of this monocyclic scaffold generated the FAAH- 
and endocannabinoid substrate-specific COX-2 dual inhibitors (2-(2-methoxy-3- 
hydroxy-)phenylamide and dopamide) which are probes with a novel 
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pharmacological profile (Figure 1.9). The dopamide is a potent and selective 
endocannabinoid substrate-specific COX-2 inhibitor, as well as the propylamide, the 
2-propenylamide and the 2-(2-methoxy-3- hydroxy-) phenylamide. Between these, 
the first two showed CB2 receptor agonistic effect coupled with a reversible and 
competitive inhibition of FAAH, while the third is not able anymore to bind the CB2 
receptor but behaves as dual enzymatic inhibitor of FAAH and COX-2 in a substrate-
specific manner (Chicca et al. 2014). 
 
 
Figure 1.9 Chemical structure of the BCP derivates. (Chicca et al. 2014) 
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2. Aims of thesis 
CB2r activation has been reported to exert protective effects in liver ischemia-
reperfusion (I/R) mouse model (Bela Horvàth et al. 2012), by reducing tissue 
damage and promoting liver regeneration following acute insult, via distinct 
paracrine mechanisms involving hepatic myofibroblasts (Teixeira-Clerc et al. 2010). 
Furthermore CB2r activation showed  beneficial effects also in alcohol-induced liver 
inflammation by regulating M1/M2 balance of Kupffer cells,  thereby reducing 
hepatocyte steatosis via paracrine interactions between Kupffer cells and 
hepatocytes (Louvet et al. 2011). Unfortunately, CB2 agonists are still not  available 
for therapeutic use. 
CB2r are primarily expressed in immune cells and β-caryophillene (BCP), which has 
anti-inflammatory and analgesic properties (Gertsch et al. 2010), can activate this 
receptor: taken in account the CB2r location in the body, BCP may be exploit for 
therapeutic purposes on inflammatory conditions. 
My main work was a part of a bigger study that aimed at investigating the 
protective effects of BCP on liver injury induced by chronic alcohol intake in mice. 
Moreover since BCP is a FDA approved food additive (Gertsch et al. 2008), it may 
have an important therapeutic utility and an immediate translational potential. 
The thesis was performed in the research group of Prof. J. Gertsch at the Institute of 
Biochemistry and Molecular Medicine of the University of Bern (Switzerland) and it 
was  mainly focused on the method development for BCP quantification which was 
applied to measure its levels in mouse tissues (liver, kidney, serum, heart and brain) 
after oral and intraperitoneal administrations. To evaluate BCP kinetics, a group of 
animals received a single dose per os or i.p and were sacrificed after different time 
points (0-360 min).  In another group of mice, it was investigated the effects of 5% 
ethanol added to the standard diet for 10 days on BCP kinetics. 
I also quantified the levels of endocannabinoids, N-acetylethanolamines, 
arachidonic acid, prostaglandins, corticosterone and  progesterone in all the tissues 
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applying an established LC-MS/MS method. The aim was to assess any potential 
effect of BCP on these metabolites.  
As an additional part of the thesis, Chicca at al. already showed that modification on 
the open-ring of BCP, that leads to an amide functionalization, can generate 
compounds that showed unique polypharmacological profiles in the ECs (Chicca et 
al. 2014). Because of this, I tested a small library of 12 additional BCP derivatives 
synthetized in the  group of Prof. G. Appendino at the University of Piemonte 
Orientale. These compounds were tested on endocannabinoid degrading enzymes 
(MAGL, FAAH, ABHDs, COX-2), cannabinoid receptors (CB1 and CB2) and the putative 
membrane transport of endocannabinoids (EMT) (Chicca et al. 2012). 
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3. Materials and Methods 
 
3.1. Materials 
 
3.1.1. Chemical and reagents 
All chemicals and reagents used for LC-MS/MS and GC-MS were of the purest 
analytical grade. AEA, AEA-d4, 2-AG, 2-AG-d5, PEA, PEA-d5, OEA OEA-d4 LEA, LEA-
d4, arachidonic acid (AA) AA-d8, PGD2, PGE2, corticosterone, progesterone and 
corticosterone were purchased from Cayman Chemical Europe, Tallinn, Estonia. 
HPLC-grade methanol (CH3OH), HPLC-grade acetonitrile, ammonium acetate and 
formic acid were obtained from Sigma-Aldrich, Steinheim, Germany. HPLC-grade 
ethyl acetate and hexane were obtained from Acros Organics, New Jersey, USA. 
Deionized water (18.2 MΩ × cm) was obtained from an ELGA Purelab Ultra Genetic 
system (VWS (UK) Ltd, ELGA LabWater, UK). 
PBS (Phosphate Buffer Saline), BSA (Bovine Serum Albumine), 2-OG, BCP and α-
humulene were obtained from Sigma-Aldrich, Saint Louis, MO, USA.  
All not radiolabeled compounds used in the in vitro assay (Heme, Orlistat (THL), 
WWL70, URB 597, AEA, CP-55,940, WIN-55,212-2, ADHP, Dup-697) and COX-2 
enzyme were purchased from Cayman Chemicals (Ann Arboe, MI, USA). The 
radioligand [3H]-CP-55,940 (144 Ci/mmol) were obtained from PerkinElmer Life 
Sciences (Waltham, MA, USA) as the scintillation liquid, while [Ethanolamine-1-3H]-
anandamide (3H-AEA) and [1,2,3-3H]-2-mono oloeyl rac glycerol (60 Ci/mmol) were 
obtained from American Radiolabeled Chemicals Inc. (Saint Louis, MO, USA). The 
Tris for buffer solution were purchased from AppliChem, Panreac while the DMSO 
from Carl Roth GmbH + Co. KG (Karsruhe). 
 
 
20 
 
3.1.2. Animals treatment 
51 males, 10–week-old C57BL/6J mice, were used for the experiments and were 
obtained from the Jackson Laboratory (Bar Harbor, ME). Animal experiments were 
performed in accordance with the National Institutes of Health (NIH) guidelines and 
approved by the Institutional Animal Care and use Committee of the National 
Institute on Alcohol Abuse and Alcoholism (Bethesda, MD). 
The animals were divided in two groups: the first was fed with normal diet (regular 
pelleted chow, NIH-31 open formula for mice and rats, Envigo) and animals were 
injected with BCP at 10mg/kg dissolved in DMSO-Tween-Saline in a ratio of 1:1:18. 
The second group was fed with a liquid diet supplemented either with, 5% ethanol 
(Lieber-DeCarli ‘82 Shake and Pour ethanol liquid diet, Bio-Serv) or isocaloric diet 
(Lieber-DeCarli ‘82 Shake and Pour control liquid diet, Bio-Serv); all animals in the 
second group were injected once daily with BCP (10mg/kg) or vehicle 
intraperitoneally, for 10 days. 
All animals were sacrificed 30 min, 1 hour, 3 hours and 6 hours after the last 
administration of BCP or vehicle. For each condition three animals were used. 
 
 
 
3.2. Methods 
  
3.2.1. LC-MS/MS 
 
3.2.1.1. Sample extraction 
To extract the endocannabinoids, N-acetylethanolamines, arachidonic acid, 
prostaglandins, corticosterone and progesterone, tissues (liver, kidney, brain, heart) 
were weighted when still frozen and transferred in 2 mL Microcentrifuge vials 
(XXTuff Microvials, BioSpec, Oklahoma, USA) containing 3 chrome-steel beads 
(BioSpec Products, Bartlesville, OK, USA) and 0.1 M formic acid (FA) (the volume 
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used depended on the amount and type of tissue: for brain, kidney, heart, 1.5 mL of 
0.1 M FA were added, instead for liver tissue 700 μL were added). Tissues (apart 
from the serum) were smashed using the mini bead beater (BioSpec Products, Inc, 
Bartlesville, OK, USA) until the complete homogenization. The homogenized tissue 
(500μL) was rapidly transferred to glass tubes containing 1.5 mL of ethyl 
acetate/hexane (9:1) 0.1% FA and 5μL of ISs mixture (internal standards), strongly 
vortex for 30 seconds and sonicated in cold bath for 5 mins. Samples were 
centrifuged at 3’000 rpm for 10 min at 4°C and kept for 1h at -20°C to freeze the 
aqueous phase. The upper organic phase was recovered in plastic tubes, dried in a 
speed vacuum and the extracts reconstituted in 50 µL of ACN/EtOH (8:2). 10 µL of 
the solution were injected in the LC-MS/MS system.  
3.2.1.2. LC-MS/MS conditions 
A hybrid triple quadrupole 4000 QTRAP mass spectrometer (AB Sciex Concord, 
Ontario, Canada) was used with a Shimadzu UFLC (Shimadzu Corporation, Kyoto, 
Japan) with cooled autosampler. Sample temperature was maintained at 4°C in the 
autosampler prior to analysis. The LC column were Reprosil-PUR C18 column (3 μm 
particle size; 2 × 50 mm, Dr. A. Maisch, High Performance LC-GMBH, Ammerbuch, 
Germany) maintained at 40° C with a mobile phase flow rate of 0.3ml/min (positive 
mode) or 0.35ml/min (negative mode). The mobile phase composition as well as the 
gradient method were different according to the operating mode. In negative mode 
the elution mobile phases were: a mixture of water, 2 mM ammonium acetate 0.1% 
FA (solvent A) and acetonitrile 0.1% FA (solvent B) to minimize crosstalk between 
analytes with the same mass ([M-H]-, m/z 351 PGE2-D2). The organic mobile phase 
(B) was substituted with methanol 2 mM ammonium acetate when operating in 
positive mode. In the negative mode the gradient started at 5% acetonitrile 0.1% 
FA, increasing linearly to 40% at 3 min, then to 65% at 9 min and increasing linearly 
again to 95% at 10min; this was maintained until 14 min, with subsequent re-
equilibration at 5% for further 3 min (Figure 3.1). 
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Figure 3.1 Gradient curve of acetonitrile 0.1% formic acid (%B in the figure) in the negative mode. 
In the positive mode gradient started at 15% methanol 2 mM ammonium acetate 
for 0.50 min, increasing linearly to 70% at 3.50 min, then increasing linearly again to 
99% at 8 min; this was maintained until 12 min then decrease to 15% at 13min with 
subsequent re-equilibration for further 2.60 min (Figure 3.2). 
 
Figure 3.2 Gradient curve of methanol 2 mM ammonium acetate (% B in the figure) in the positive mode. 
Identification of compounds in samples was confirmed by comparison of precursor 
and product ion m/z values and LC retention times with standards. In the following 
figure are shown the typical extracted ion chromatogram and retention times used 
for the identification of the compounds. 
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Figure 3.3 Typical extracted ion chromatogram and retention time of 2-AG, AEA, AA, NE, Progesterone, 
Corticosterone, PGE2, PGD2, LEA, OEA and PEA. 
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Peaks were integrated, and the Analyst software version 1.5 (AB Sciex Concord, 
Ontario, Canada) was used to quantify levels of interested analytes. The following 
MRM transitions were monitored for quantification of the analytes: Negative mode: 
PGE2, m/z 351 271, 351 315; PGD2 351 189.1 (PGE2-d4 355 319); AA 303 59, 
303 259 (AA-d8 311 59). Positive mode: 2AG, m/z 379 203, 379 287 (2-AG-d5 
384 287); AEA 348 62, 348 133 (AEA-d4 352 66); Corticosterone 347 135, 
347 121, 347 97 (COR-d4 367 121); LEA, 324 62, 324 109 (LEA-d4 328 66); 
OEA, 326 309, 326 62 (OEA-d4 330 66); PEA, 300 283, 300 62 (PEA-d5 
305 62); Progesterone 315 97, 315 109 (PROG-d9 324 100). Triplicate 11 
points calibrations were prepared in 0.1 formic acid plus 1%BSA and an aliquot of 
the appropriate matrix. To ensure that were constant background concentration of 
all endogenous analytes, bulk tissues were homogenized and used for validation 
experiments and calibration data set (the background was subtracted to spiked 
concentration levels). The concentration of standards range was from 20 ng/mL to 
50000 ng/mL for AA, from 0.2 ng/mL to 500 ng/mL for LEA, PEA, OEA, PGD2, PGE2, 
Corticosterone. For AEA and Progesterone the calibration moves in a range of 0.08 
ng/mL to 200 ng/mL, and for NE and 2-AG from 2 ng/mL to 5000 ng/mL. The 
concentration range of calibration curves and the amount of ISs were specifically 
design to measure the amount of the analytes in the biological matrix to be studied. 
The ratio (peak area of each analyte/peak area of internal standard), was calculated 
and used to ensure linearity of the method. The slope, intercept, and regression 
coefficient of those calibration lines were determined. Analytes amount were 
normalized to the tissue weight and plotted with GraphPad Prism 5®.  
The statistical significance among groups was determined using a one-way ANOVA 
test followed by Tukey’s test. Statistical differences between control and treated 
groups were considered as significant if *P 0.05 (**P 0.01 and ***P 0.001). 
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3.2.1.3. LC-MS/MS validation 
Coefficient of Variations in intra-day (n=6) and inter-day (n=6 over 3 separate days) 
recovery, matrix factor and accuracy were determined at three concentrations (liver 
was used as matrix) representing the entire range of concentration (low quality 
control, medium quality control, high quality control) (Table 3.1). Accuracy was 
calculated as the following, accuracy = (mean calculated concentration/nominal 
concentration) x 100, while matrix factor = (peak area of analyte spike after 
extraction /neat solution), then CV = (standard deviation/mean calculated 
concentration) x 100 and recovery = (peak area of analyte/ neat solution) x 100. For 
all the analytes the matrix factor is in the range (100%, so no matrix effect) apart 
from the N-acetylethanolamines, which are anyway minor analytes, where an ion- 
suppression is observed, instead the recovery is in the range for all of them (100%). 
For the analytes, since they are naturally present in the matrix, recovery was 
calculated by comparison of deuterated analogue (IS). All the parameters were 
considered acceptable when within 20% (CV has to be < 20 %)(Table 3.1). 
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Analyte Nominal 
Concentration 
(ng/mL) for 
LQC, MQC, HQC 
Intraday (n=6) Interday (n=6) 
  Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
      
 8 123.80 19.29 107.45 9.19 
2-AG 64 99.9 11.25 100.65 6.28 
 800 98.47 7.32 103.18 5.75 
 
 0.32 114.48 8.43 117.81 8.10 
AEA 2.56 101.05 4.70 109.37 7.96 
 32 101.31 4.28 111.61 10.95 
 
 0.8 75.33 16.10 107.69 8.97 
LEA 6.4 101.80 7.05 105.63 7.87 
 80 98.25 5.16 113.22 12.71 
 
 0.8   120.71 31.90 
PEA 6.4 84.09 12.19 106.58 8.08 
 80 105.32 7.72 111.89 5.13 
 
 0.8 111.58 18.19 129.35 9.77 
OEA 6.4 101.23 9.23 112.74 2.22 
 80 106.38 5.93 112.05 7.89 
 
 0.8 176.46 23.09 102.13 21.61 
CORTICOS 6.4 98.70 7.86 111.39 18.33 
 80 107.71 6.85 114.67 28.34 
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 0.32 109.65 5.85 113.73 6.78 
PROGEST 2.56 101.28 5.45 105.77 5.67 
 32 99.64 6.59 104.99 7.66 
 
 8 62.56 60.69 79.65 30.92 
NE 64 55.76 12.77 107.71 20.93 
 800 131.72 10.26 109.44 23.19 
 
 0.8 109.51 11.89 103.79 7.33 
PGD2 6.4 95.54 4.36 103.10 5.35 
 80 103.03 6.17 106.37 6.94 
 
 0.8 124.18 10.65 124.78 19.58 
PGE2 6.4 98.22 6.35 107.06 5.74 
 80 108.44 5.11 103.91 6.09 
 
 0.8 160.42 33.49 104.85 22.92 
AA 6.4 119.45 8.35 107.98 13.37 
 80 100.50 7.29 114.44 11.96 
 
Table 3.1 Table of accuracy and CV for endocannabinoids, N-acetylethanolamines, arachidonic acid, 
prostaglandins, corticosterone and progesterone. 
 
3.2.2. GC-MS 
 
3.2.2.1. Sample extraction 
100 μL of the same homogenized tissue in 0.1 M FA, used for lipids extraction, (see 
above) were used for extracting BCP. The homogenized tissue was rapidly 
transferred to plastic tubes with 90 μL of ethyl acetate and 10μL of α-humulene in 
ethyl-acetate (used as Internal Standard), strongly vortex for 30 seconds and 
sonicated in cold bath for 5 min. Samples were centrifuged at 3’000 rpm for 10 min 
at 4°C and kept for 1h at -20°C to facilitate the recovery of the upper organic phase. 
1 µL of the solution were injected in the GC-MS system.  
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3.2.2.2. GC-MS conditions 
An Agilent 5675C inert XL Mass Selective Detector (MSD) with triple-axes detector 
was used with an Agilent 6890N Gas Chromatography (GC) and Gerstel cooled 
injection system CIS 4. Sample temperature was maintained at 7°C in the 
autosampler prior to analysis. A HP-5ms Ultra Inert capillary column (30m x 0.25 
mm i.d.) coated with a 0.25 μm thick film of (5%-Phenyl)-methylpolysiloxane 
(Agilent Technologies) was used as stationary phase. Separation of BCP and its 
internal standard was achieved with the following oven program:  the initial 
temperature was 100°C, then was programmed to 120°C at 15°C/min, holding for 
0.50 min, followed by 7°C/min to 180°C and held for 1 min. After that the column 
was cleaned for 1 min at 20°C/min to 310°C (Figure 3.4). 
 
Figure 3.4 Temperature oven curve of GC-MS used for the quantification of BCP. 
Helium was used as carrier gas at a constant flow rate of 1.0mL/min. The sample 
volume was 1μL and the inlet was in the splitless mode. Ionization was carried out 
in electron impact (EI) mode. The detection was operated in SIM mode:  from 7.1 to 
7.2 min, m/z 93 (α-humulene) and from 6.7 to 6.9 min, m/z 91 (BCP) were 
respectively selected for quantification as their relative abundance was one of the 
highest in individual full mass spectrum (Figure 3.5 and Figure 3.6). Data were 
analysed using Microsoft Excel Worksheet and plotted with GraphPad Prism 5®. 
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Figure 3.5 Fullscan of α-humulene. 
 
 
Figure 3.6 Fullscan of BCP. 
 
 
3.2.3. [3H] CP-55,940 competition binding assay 
The binding assay was performed using 15 μg of CB1r/CB2r Chinese Hamster Ovary 
(CHO) membranes overexpressing CB1/CB2 receptors per sample, in 300 μL of assay 
buffer (Tris-HCl 50 mM, EDTA 2.5 mM, MgCl2 5mM, 5% fatty acid free BSA, pH 7.5). 
CHO membranes were kindly provided from other members of the laboratory. 
Before starting PEI (polyethyleneimine) solution (0,5 g dissolved in 100 mL di-
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distillated H2O) was added to the GF-B filter-plate to make the filter able to work in 
a better way. 3μL of ligand or control solvent, in our case DMSO, (finally 1% of 
solvent) were added to the samples, and in two wells (R)-WIN55,212-2 (10μM) was 
added to determine the non-specific bond. Afterwards [3H] CP-55,940 (0.5 nM) was 
added, the samples were vortex and left at RT for 90-120 min. After the incubation 
time the plate was put on the vacuum and washed 2x with 100 μL assay buffer. The 
samples were loaded onto the filter in 2 steps and each well was washed 10/12x 
with 100 μL assay buffer. The plate was dried at room temperature or under a drier 
flow. Then a transparent foil was attached on the bottom of the plate and 45 μL of 
MicroScint20 were added and the top of the plate was closed with another 
transparent foil. The plate was shaked for 20 min and the radioactivity (cpm) was 
measured. 
Results were analyzed with GraphPad Prism 5®and expressed as bound of [3H] CP-
55,940 (% of control). Ki values were calculated using the Cheng-Prusoff formula: Ki 
= IC50 / 1 + [L]/ Kd. 
The assay was also performed with two variations: instead of pipetting the BCP in 
the tubes without extracting them from the rack, all the tubes were removed and 
the compound was added in the middle of the binding buffer. The other change was 
that all the tubes were not vortex together, but every single one was vortex strongly 
by itself. Then the assay was carried out as described above. 
 
3.2.4. Hydrolysis assay 
In order to evaluate the inhibitor power and the selectivity of the BCP derivates, we 
performed enzyme activity assays (FAAH, MAGL, ABHD-6 and ABHD-12, COX-2) 
using the corresponding radiolabeled substrates (2-OG, 2-AG, AEA or AA) to follow 
the amounts of the hydrolytic product. 
3.2.4.1. FAAH activity assay 
The assay was performed in silanized Eppendorf tubes using 0.5 Mio of U937 cells 
per sample. Cells were kindly provided from other members of the laboratory. The 
homogenate was diluted in the activity buffer (10mM Tris-HCl, 1mM EDTA, 0.1% 
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(m/v) BSA, pH 8.0) then they were mixed together and split in the tubes with a final 
volume of 500 μL. 5μL of tested compounds (1% solvent) or vehicle (DMSO) were 
added, the tubes were vortex and incubated 15 min at 37°C in the thermomixer 500 
rpm. Inhibitor URB-597 [1 µM] was used as positive control. The AEA mix ([3H] AEA 
(16nM) + AEA (14.4 μM)) was added to the homogenate (1:50), shaked with vortex 
and incubated other 15 min at 37°C and 500rpm in the thermomixer. The reaction 
was stopped with 1 mL of cold mix CCl3:MeOH (1:1), vortexing and place on ice. 
Then the tubes were centrifuged at 4°C for 10 min 16’000 rpm and 800 μL of the 
upper aqueous phase were transferred into the scintillation vial with 3 mL of 
scintillation cocktail. Finally, the vials were shaken for 10 min and signal was 
detected with TRICARB 2100TR scintillation counter and results were analyzed with 
GraphPad Prism 5®and expressed as [3H] AEA hydrolysis (% of vehicle).  
The assay was also performed with a variation: instead of doing a pre-incubation 
time of 15 min and an incubation time of 15 min, 5 μL of the control, tested 
compounds and the inhibitor were added and immediately afterwards also the AEA 
mix was added to the tubes. Then they were vortex and co-incubated for 10 min at 
37°C 500 rpm. Then the assay was carried out as described above. 
 
3.2.4.2. ABHDs activity assay 
Enzyme activity inhibition was conducted in silanized Eppendorf tubes with a final 
volume of 200 μL per sample. The homogenate was prepared from HEK293T-ABHD-
12 or HEK293T-ABHD-6 and HEK293T as non-transfected cells as control. All the 
cells were kindly provided from other members of the laboratory. For each sample 
was added a mix of 193 μL made up of membrane and assay buffer (10 mM Tris HCl, 
1 mM EDTA, 0.1 % BSA, 46,5% PBS pH 8.0). 2 µL of tested compounds (1% solvent) 
or vehicle were added, tubes were pre-incubated for 30 min at 37 °C and 500 rpm in 
the thermomixer. The positive controls were THL [20 μM] for ABHD-12 and WWL70 
[10μM] for ABHD-6. Afterwards 5 μL of 2-OG mix ([3H]-2OG in the glycerol moiety 
10 μM final 1:8000) were added and incubated again at 37°C for 5 min 500 rpm in 
the thermomixer. In both cases the hydrolysis was stopped with 400 μL of cold mix 
CCl3:MeOH (1:1), vortexing and place on ice. Then the tubes were centrifuged at 4°C 
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for 10 min 16’000 rpm and 200 μL of the upper aqueous phase were transferred 
into the scintillation vial with 3 mL of scintillation cocktail. After shaking time, signal 
was detected with TRICARB  2100TR scintillation counter and results were analyzed 
with GraphPad Prism 5®and expressed as [3H]2-OG hydrolysis (% of vehicle). 
 
3.2.4.3. MAGL activity assay 
Enzyme activity inhibition was conducted in silanized tubes using 0.5 Mio of U937 
homogenate cells per sample in 500 µL of assay buffer (10 mM Tris HCl, 1 mM 
EDTA, 0.1 % BSA, pH 8.0). Cells for the homogenate were kindly provided from 
other members of the laboratory. 5 µL of URB-597 [1 µM] was added and tubes 
were pre-incubated for 20 min at 37°C 500 rpm in the thermomixer to minimize the 
effect of other endocannabinoid enzymes in the reaction matrix. After that, 5 μL of 
tested compounds (1% solvent) or vehicle (DMSO) were added in the samples and 
incubated for 15 minutes, at 37°C and 500 rpm. Inhibitor JZL-184 [1 µM] was used 
as positive control.  5μL of the 2-OG mix ([3H] 2-OG [16.7 μM] + 2-OG [10 mM]) was 
added in the tubes and incubated for 15 minutes, at 37°C and 500 rpm. The reaction 
was stopped with 1mL of ice-cold mix CCl3:MeOH (1:1 v/v), mixed well and 
centrifuged for 10 minutes, at 0 °C and 16'000 rpm. 400 µL of the upper aqueous 
phase was collected in scintillation vials and 3 ml of scintillation liquid was added in 
each vial.  After shaking time, signal was detecting with TRICARB  2100TR 
scintillation counter and results were analyzed with GraphPad Prism 5®and 
expressed as [3H]2-OG hydrolysis (% of vehicle). 
 
3.2.4.4. COX-2 activity assay 
For the assay a Grainer Bio One 384 plate was used. A master mix was prepared and 
split in the wells. Each one contains 37.5 μL of COX Activity Buffer (CAB) (Tris-HCl 
0.1 M pH=8), 2.5 μL of Heme (5 μM final concentration), 2.5 μL ADHP (10-acetyl-3,7-
dihydroxyphenoxazine) and 2.5 μL of COX-2 run solution (55.5 U/μL) apart from the 
blank wells where the 2.5 µL of enzyme were replaced with buffer. Dup-697 (5 μM 
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as final concentration) was used as positive control. Then, 2.5 µL of inhibitor or 
vehicle (DMSO) or buffer (blank) were added to have a final volume per wells of 50 
μL. The plate was left at RT for 30 min. Then 2.5 µL of AA or 2-AG or AEA [10 µM in 
final concentration] were added to each well. Immediately the signal was detected 
with FarCyte Fluorescence Polarization Exc. 535nm / 580nm), cycling mode, with at 
least 10 cycles (Gain = 50; Z = 8083; CyclinG: with the lowest interval). Results were 
expressed as COX-2 activity (% of vehicle) with GraphPad Prism 5®. 
 
3.2.5. AEA uptake assay 
The assay was performed using 0.5 Mio U937 cells in RPMI medium per 250 μL in 
silanized plastic tubes. Cells were kindly provided from other members of the 
laboratory. The pre-incubation time was 15 min at 37°C in the thermomixer with 5 
μL of tested compounds or vehicle (DMSO). UCM-707 and OMDM-2 were used as 
positive controls at concentration of 10 µM (500 μM final concentration). 5 μL of 
AEA mixture (100nM in final concentration) ([3H] AEA (167 nM) + AEA (14.4 µM)) 
were added and incubated for 15 min at 37°C. Afterwards samples were loaded 
onto GF/C filter pre-soaked with 100 μL of PBS 1% BSA and washed 3x with 150 µL 
of PBS 1% BSA. The plate was dried at room temperature or under a drier flow and 
the bottom was covered with a transparent foil. Then, 45 µL MicroScint20 were 
added to each sample and the top closed with a foil as well. The plate was 
incubated for 20 min and the radioactivity (cpm) was measured. The results were 
plotted with GraphPad Prism 5® and signal was expressed as [3H] AEA uptake (% of 
vehicle). 
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4. RESULTS and DISCUSSION 
During the work of my thesis I developed a quantification method for BCP based on 
gas chromatography–mass spectrometry (GC-MS) . I applied this method to quantify 
BCP in mouse tissues of C57BL/6J mice 10 –week-old males. The animals were 
divided in two groups: the first, was administered a single dose of BCP given 
intraperitoneally or oral, while the second group received BCP or vehicle BCP or 
vehicle i.p. every day for 10 days. Furthermore, the second group of mice was fed 
either with 5% ethanol supplemented liquid diet or isocaloric liquid diet (see section 
Materials and Methods). 
The animal experiments were performed in the laboratory of Prof. P. Pacher at the 
NIAAA/NIH (Bethesda, US). We received different organs (liver, kidney, brain, heart) 
and serum for measuring BCP distribution. 
4.1. Method optimization for BCP quantification 
BCP is a volatile compound (in fact is present in the essential oils of the plants), and 
this property conditioned the choice of the machine used for the quantification as 
well as the way of handle it. 
As a first step, we tried to inject the BCP in the Liquid chromatography–mass 
spectrometry/ mass spectrometry (tandem mass spectrometry) (LC-MS/MS), to 
assess whether the molecule was detectable with this machine, but unfortunately 
this was not possible because it did not ionize in both the negative and positive 
mode (inosation is the process whereby electrons are either added or removed to 
molecules to product ions, respectively negatively or positively charged, that will be 
detect by the mass spectrometer) and for that reason was stuck into the column. So 
we tried with the GC-MS which is also reported in the literature to be a valid 
method for the quantification of volatile compounds. Thanks to the improvement 
carried out, we obtained a nice peak in the chromatogram. The first injection of a 
new compound that has to be detect, is always performed at a higher concentration 
compare to the ones that is usually present in the samples, but even decreasing the 
BCP concentration we were able to obtain an intense signal. 
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The next issue was the GS-MS volume of injection: to have a tight peak in the 
chromatogram, is recommended to inject a low amount of sample, in order to 
enable the machine to accurately evaporate and give a not broad signal in the 
chromatogram. In our case the volume of injection was 1 μL. In general this is not a 
problem because the machine is sensitive enough, but with the BCP was a problem 
due to its volatility. Thus we tried to concentrate the samples after extraction, 
using  nitrogen or a speed vacuum concentrator, but it was not possible. During this 
procedure, BCP was also evaporated leading to the complete loss of signal 
detection. 
Following up what said above, the extraction solvent has a essential role to measure 
BCP. Liu. et al.‘ used ethyl acetate for BCP extraction, therefore we tried the same 
procedure. In the light of the high lipophilicity of BCP we also used hexane which is 
a more apolar solvent.  To compare the two methods, we performed the extraction 
using three concentrations of BCP (80, 320, 1600 ng/mL) and calculated for all of 
them the % of recovery (that can be defined as amount of the analyte added to and 
extracted from the biological matrix, compared to the amount obtained for the true 
concentration of the pure authentic standard) (Table 4.1). Recovery of the analyte 
need not to be 100%, but the extent of recovery of an analyte and of the internal 
standard should be consistent, precise, and reproducible (Guidance for industry-
Bioanalytical method validation). 
 
 
Table 4.1 Comparative table of the two possible extraction solvents: ethyl acetate and hexane. 
As shown in the table above, the recovery is higher with hexane for the low and the 
high levels, not for the intermediate concentration, which is actually the most 
important because the values in the middle of the calibration curve are more 
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precise compare to the extremes. The difference of the two hypothetical 
calibrations is visible also in Figure 4.1 : the first two points are almost overlapping 
and the third ones are anyway very close to each other.  
 
Figure 4.1 Hypothetical calibrations with ethyl acetate and hexane 
The solvent selection was carried out taking in account multiple aspects: first of all 
the little differences among the two extraction methods allows us to choose both of 
them. Then hexane is more toxic compare to ethyl acetate. Finally the major 
component of the extraction mixture in the LC-MS/MS method (see section 
Materials and Methods) is ethyl acetate: the amount of serum was not enough to 
perform two different extraction to analyze both BCP and the other analytes. 
Considering all these things, ethyl acetate was chosen to perform the 
measurements.  
At this point we focused our attention on the only factor that we could modulate: 
the temperature reached by the machine to obtain a good ionization of BCP and a 
nice peak in the chromatogram. We used as starting point the table temperature 
published by Liu et al.: the oven temperature was initially held at 100°C, then was 
programmed to reach 140°C at 15°C/min, holding for 0.5 min, followed by 30°C/min 
to 280°C and held for 3 min. Then, we started to work on the ramping temperature 
(temperature per minute), the temperature and the holding time, to improve the 
separation of the retention time (RT) between the BCP and the IS (α-humulene). For 
the quantification is important that the investigated analyte and its IS do not 
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overlap each other, so we try to separate the RT of BCP and α- hunulene as much as 
possible. Once a difference of 0.5 min among the two compounds was obtained (RT 
for α-humulene is around 7.2 and for BCP is around 6.7), we try to reduce the time 
spent on each sample run, without affecting the other parameters. Finally, to clean 
the column after the run, in order to avoid contamination on the following 
measurements, we added another ramp to the oven which let the machine rise a 
very high temperature (Table 4.2). 
 
 
Table 4.2 Table of the final setting of the GC-MS oven. 
4.1. BCP quantification in mouse tissues by GC-MS 
The graphics below will present the quantification of BCP in the tissues investigated: 
liver, kidney, serum, heart and brain. For each one on the left panel are shown the 
data of the mice that receive the compound once or ip or oral. On the right panel 
there are the data of mice that received every day BCP or vehicle for 10 days and 
where fed with the two liquid diets. 
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Figure 4.2 Quantification of BCP in (a) liver, (b) kidney, (c) serum, (d) brain, (e) heart. Mean ± SD. 3 mice per 
group. >LOD=  below limit of detection. 
 
b 
39 
 
Results showed that in all the tissues measured at lower time points (30-60 min) 
BCP was detectable in all three mice per group, while at later time points (180-360 
min) BCP was below the limit of detection or measurable only in one or two out of 
three mice per group. 
In the liver (Figure 4.2-a) the amount of BCP present in the mice that were injected 
intraperitoneally, was higher compared to the mice that received the same amount 
per os. Considering the amount of BCP in both the two liquid diets, the 
concentration are around three times more compare the single intraperitoneal 
injection and there are no significant differences between them.  
In the kidney (Figure 4.2-b) BCP was detectable only at 30 min when administered 
orally and was two times lower compare to the i.p. injected mice. For what concern 
the two liquid diets, the compound was in general detectable in all conditions 
without significant differences  over time. 
For the serum, the brain and the heart (Figure 4.2 c-e) there was a similar tendency 
with BCP decreasing over time becoming below the limit detection after 1 hour 
after injection. In the serum, the amount of BCP detect after 30 min in the animals 
fed with normal diet is two times more compare to the animals that where fed with 
the two liquid diet.  Instead if we analyze the other two tissues, the heart and the 
brain, we can evaluate an opposite condition, i.e. a BCP concentration higher for the 
mice fed with the liquid diets. 
The fact the BCP was measurable only at lower time point might not be necessary 
linked to a complete elimination from the tissue, but is possible that residual 
amount of BCP can still be present in tissues at bioactive concentrations (i.e. 100-
200 nM) which are below the limit of detention. In addition, another possibility is 
related to the potential formation of BCP metabolites which might still have 
bioactive properties and that we are unable to detect with our quantification 
method. Furthermore, if we compare the results obtained for the kidney in the two 
groups of animals, is interesting to see that the levels of BCP remained constant 
over the whole time-course in the animals which received repeated injections for 10 
days, while in the single injection experiment, BCP was below the limit of detection 
as early as after 60 min after administration. On the contrary, upon 
single administration, BCP was below the limit of detection as early as after 60 min 
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from the injection. This difference suggest that BCP either is retained in the kidney 
or reabsorbed in the nephron. Due to its high lipophilic nature, we can hypothesize 
that BCP could be reabsorbed bound to plasma proteins (i.e. albumin) and then 
reintroduced in the bloodstream. In this scenario, the kidney might act as a 
reservoir for BCP which is slowly distributed to the other organs. A simple tissue 
accumulation is unlikely, because over days of treatment BCP levels should increase 
compared to a single injection, which is not the case. An alternative explanation of 
the renal accumulation of BCP could be the excretion with the urine. However, due 
to its low aqueous solubility, it is unlikely that BCP would be mostly excreted in the 
urine. More experiments are necessary in order to test these hypothesis. 
Finally, if we compare mice treated with single administration of BCP given 
intraperitoneally or oral, we can see that the different administrations did not lead 
to any statistically significant difference between the two conditions. This indicates 
a potential good bioavailability of this natural compound. Considering then the 
other group of animals (pair-fed vs. ethanol-fed  mice), the results suggest that the 
distribution of BCP seems not to be affected by the different liquid diets (5% 
ethanol vs. isocaloric diet), in fact the concentration at the related time point is 
almost the same with the only exception of the kidney. 
 
4.2. Endocannabinoids and other lipids quantification 
in mouse tissue by LC-MS/MS  
The graphics below will show the quantification of endocannabinoids, N-
acetylethanolamines, arachidonic acid, prostaglandins, corticosterone and  
progesterone carried out with the LC-MS/MS in liver, kidney, serum, heart and 
brain. On the left panels there are the data for the mice that received the 
compound only once ( Ip. vs Oral), while on the left panels there are the data for the 
mice that received or BCP or vehicle every day for 10 days and where fed with the 
two liquid diet ( Pair –fed vs. Ethanol-fed diet). 
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4.3.1. Liver 
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Figure 4.3 Liver analytes: (a) 2-AG Ip. vs. Oral administration, (b) 2-AG Pair-fed vs. Ethanol-fed diet, (c) AEA Ip. 
vs. Oral administration, (d) AEA Pair-fed vs. Ethanol-fed diet, (e) NE Ip. vs. Oral administration, (f) NE Pair-fed vs. 
Ethanol-fed diet, (g) progesterone Ip. vs. Oral administration, (h) progesterone Pair-fed vs. Ethanol-fed diet, (i) 
corticosterone Ip. vs. Oral administration, (j) corticosterone Pair-fed vs. Ethanol-fed diet, (k) AA Ip. vs. Oral 
administration, (l) AA Pair-fed vs. Ethanol-fed diet, (m) PGE2 Ip. vs. Oral administration, (n) PGE2 Pair-fed vs. 
Ethanol-fed diet, (o) PGD2 Ip. vs. Oral administration, (p) PGD2 Pair-fed vs. Ethanol-fed diet, (q) LEA Ip. vs. Oral 
administration, (r) LEA Pair-fed vs. Ethanol-fed diet, (s) OEA Ip. vs. Oral administration, (t) OEA Pair-fed vs. 
Ethanol-fed diet, (u) PEA Ip. vs. Oral administration, (v) PEA Pair-fed vs. Ethanol-fed diet . * p < 0.0.5 vs. vehicle; 
# p < 0.01 vs. Oral. 
 
In the liver, 2-AG levels showed a tendency to increase overtime (Figure 4.3 a) that 
is no more visible in the mice of the other group (Pair-fed vs. Ethanol-fed diet) while 
in both cases AEA levels (Figure 4.3 c-d) were the same as well as for AA, LEA, OEA 
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and PEA (Figure 4.3 k-l, q-r, s-t, u-v). Intriguingly, noladin ether (NE) at the later time 
points significantly decreased (Figure 4.3 e) unlike in Pair-fed vs. Ethanol-fed diet 
(Figure 4.3 f). Progesterone levels were significantly higher at 30 min after i.p. 
injection compared to oral administration (Figure 4.3 h). The corticosterone seems 
to decrease when is given ip. but has an opposite tendency when is given per os 
(Figure 4.3 i), while in the repeated doses experiments (Pair-fed vs. Ethanol-fed 
diet) it was below the limit of detection (Figure 4.3 j). Prostaglandin E2 (PGE2) was 
below the limit of detect (PGE2 Figure 4.3 m-n), while prostaglandin D2 (PGD2) was 
quantifiable only in few mice (PGD2Figure 4.3 o-p).  
 
4.3.2. Kidney 
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Figure 4.4 Kidney analytes: (a) 2-AG Ip. vs. Oral administration, (b) 2-AG Pair-fed vs. Ethanol-fed diet, (c) AEA Ip. 
vs. Oral administration, (d) AEA Pair-fed vs. Ethanol-fed diet, (e) NE Ip. vs. Oral administration, (f) NE Pair-fed vs. 
Ethanol-fed diet, (g) progesterone Ip. vs. Oral administration, (h) progesterone Pair-fed vs. Ethanol-fed diet, (i) 
corticosterone Ip. vs. Oral administration, (j) corticosterone Pair-fed vs. Ethanol-fed diet, (k) AA Ip. vs. Oral 
administration, (l) AA Pair-fed vs. Ethanol-fed diet, (m) PGE2 Ip. vs. Oral administration, (n) PGE2 Pair-fed vs. 
Ethanol-fed diet, (o) PGD2 Ip. vs. Oral administration, (p) PGD2 Pair-fed vs. Ethanol-fed diet, (q) LEA Ip. vs. Oral 
administration, (r) LEA Pair-fed vs. Ethanol-fed diet, (s) OEA Ip. vs. Oral administration, (t) OEA Pair-fed vs. 
Ethanol-fed diet, (u) PEA Ip. vs. Oral administration, (v) PEA Pair-fed vs. Ethanol-fed diet. * p < 0.05 vs. veichle; 
** p < 0.01 vs. veichle; # p < 0.01 vs. Oral. 
 
In the kidney, 2-AG and AEA showed the same trend for both i.p. and oral 
administrations: at 60 min there was a significant increase (Figure 4.4 a-c), while in 
the repeated doses experiment (Pair-fed vs. Ethanol-fed diet) there was no 
significant difference over time (Figure 4.4 b-d). NE (Figure 4.4 e-f), progesterone 
(Figure 4.4 g-h), corticosterone (Figure 4.4 i-j), AA (Figure 4.4 k-l), PGE2 (Figure 4.4 
m-n), LEA (Figure 4.4 q-r) and PEA (Figure 4.4 u-v) did not show any particular 
change in their abundance, while OEA (Figure 4.4 s-t) increased at 60 min in the i.p. 
injection and also at 180 min and 360 min in the oral administration (Figure 4.4 s). 
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4.3.3. Serum 
  
  
  
a b 
c d 
e f 
51 
 
      
  
  
  
g h 
k l 
i j 
52 
 
 
  
  
  
o p 
c 
m n 
q r 
53 
 
 
Figure 4.5 Serum analytes: (a) 2-AG Ip. vs. Oral administration, (b) 2-AG Pair-fed vs. Ethanol-fed diet, (c) AEA Ip. 
vs. Oral administration, (d) AEA Pair-fed vs. Ethanol-fed diet, (e) NE Ip. vs. Oral administration, (f) NE Pair-fed vs. 
Ethanol-fed diet, (g) progesterone Ip. vs. Oral administration, (h) progesterone Pair-fed vs. Ethanol-fed diet, (i) 
corticosterone Ip. vs. Oral administration, (j) corticosterone Pair-fed vs. Ethanol-fed diet, (k) AA Ip. vs. Oral 
administration, (l) AA Pair-fed vs. Ethanol-fed diet, (m) PGE2 Ip. vs. Oral administration, (n) PGE2 Pair-fed vs. 
Ethanol-fed diet, (o) PGD2 Ip. vs. Oral administration, (p) PGD2 Pair-fed vs. Ethanol-fed diet, (q) LEA Ip. vs. Oral 
administration, (r) LEA Pair-fed vs. Ethanol-fed diet, (s) OEA Ip. vs. Oral administration, (t) OEA Pair-fed vs. 
Ethanol-fed diet, (u) PEA Ip. vs. Oral administration, (v) PEA Pair-fed vs. Ethanol-fed diet. 
In the serum the concentrations of all measured metabolites did not show any 
statistically significant change, apart from prostaglandins and NE that were below 
the limit of detection (Figure 4.5 e-f, m-n, o-p). 
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4.3.4. Brain    
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Figure 4.6 Brain analytes: (a) 2-AG Ip. vs. Oral administration, (b) 2-AG Pair-fed vs. Ethanol-fed diet, (c) AEA Ip. 
vs. Oral administration, (d) AEA Pair-fed vs. Ethanol-fed diet, (e) NE Ip. vs. Oral administration, (f) NE Pair-fed vs. 
Ethanol-fed diet, (g) progesterone Ip. vs. Oral administration, (h) progesterone Pair-fed vs. Ethanol-fed diet, (i) 
corticosterone Ip. vs. Oral administration, (j) corticosterone Pair-fed vs. Ethanol-fed diet, (k) AA Ip. vs. Oral 
administration, (l) AA Pair-fed vs. Ethanol-fed diet, (m) PGE2 Ip. vs. Oral administration, (n) PGE2 Pair-fed vs. 
Ethanol-fed diet, (o) PGD2 Ip. vs. Oral administration, (p) PGD2 Pair-fed vs. Ethanol-fed diet, (q) LEA Ip. vs. Oral 
administration, (r) LEA Pair-fed vs. Ethanol-fed diet, (s) OEA Ip. vs. Oral administration, (t) OEA Pair-fed vs. 
Ethanol-fed diet, (u) PEA Ip. vs. Oral administration, (v) PEA Pair-fed vs. Ethanol-fed diet.* p < 0.0.5 vs. vehicle; 
** p < 0.01 vs. vehicle. 
 
 
 
 
  
  
s t 
u v 
58 
 
 
In the brain, 2-AG and AEA levels showed the same trend in both experimental 
groups (single and repeated doses) with a tendency to decrease over time. For both 
the analytes at 360 min the tendency become statistically significant in single 
injected mice (Figure 4.6a-b, c-d). All the other metabolites did not change (Figure 
4.6). The only exception is represented by the OEA that decreased over the time in 
the i.p. single injection similarly to AEA (Figure 4.6s). 
 
 
 
 
 
4.3.5. Heart 
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Figure 4.7 Heart analytes: (a) 2-AG Ip. vs. Oral administration, (b) 2-AG Pair-fed vs. Ethanol-fed diet, (c) AEA Ip. 
vs. Oral administration, (d) AEA Pair-fed vs. Ethanol-fed diet, (e) NE Ip. vs. Oral administration, (f) NE Pair-fed vs. 
Ethanol-fed diet, (g) progesterone Ip. vs. Oral administration, (h) progesterone Pair-fed vs. Ethanol-fed diet, (i) 
corticosterone Ip. vs. Oral administration, (j) corticosterone Pair-fed vs. Ethanol-fed diet, (k) AA Ip. vs. Oral 
administration, (l) AA Pair-fed vs. Ethanol-fed diet, (m) PGE2 Ip. vs. Oral administration, (n) PGE2 Pair-fed vs. 
Ethanol-fed diet, (o) PGD2 Ip. vs. Oral administration, (p) PGD2 Pair-fed vs. Ethanol-fed diet, (q) LEA Ip. vs. Oral 
administration, (r) LEA Pair-fed vs. Ethanol-fed diet, (s) OEA Ip. vs. Oral administration, (t) OEA Pair-fed vs. 
Ethanol-fed diet, (u) PEA Ip. vs. Oral administration, (v) PEA Pair-fed vs. Ethanol-fed diet. + p < 0.05 vs. pair fed 
diet. 
 
In the heart the levels of the analyzed metabolites were not affected by BCP in any 
of the experimental conditions (Figure 4.7). 
Altogether these data indicates that BCP does not significantly affect the levels of 
endocannabinoids and other related lipids, with only some few exception such as 
the decrease of NE in liver at later time points,  the increase of AEA and 2-AG after 
30 and 60 min after single i.p. injection in the kidney and  the reduction of 
endocannabioid brain concentration over time in both muse groups (single and 
repeated BCP administrations).  
As a general consideration on the experimental settings, the use of three mice per 
condition was too little to have a realistic estimation of the amount of the 
compound researched and this problem affected more the quantification of BCP, 
than the quantification of the analytes investigated with the LC-MS/MS, because 
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with our GC-MS quantification method we were not always able to detect BCP due 
to its volatility. Moreover was also impossible to evaluate whether vehicle (DMSO-
Tween-80-saline 1:1:18) exerted a direct effect on the metabolite levels over time, 
because the experiments did not include vehicle-injected animals for the different 
time points but only for the time 0. 
 
4.4. Biochemical evaluation of BCP and a new library of 
BCP derivatives 
 
4.4.1. CB2 receptor binding of BCP 
BCP is reported in the literature to be a CB2 selective full agonist and to shows a Ki 
in the nanomolar range (155 ±4 nM) (Gertsch et al. 2008). In order to confirm its 
capability to bind the CB2 receptor, the assay was performed using different 
concentrations of BCP: 10nM, 100nM, 1μM, 3μM, 10μM. 
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Figure 4.8 CB2 binding assay for BCP. 
The assay was performed in two ways: for the first assay were followed the 
standard binding assay conditions, while for the second BCP was carefully pipetted 
in the middle of the binding buffer volume and every tube was vigorously and 
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Figure 4.9 Chemical structures of BCP derivatives. 
separately vortex immediately after BCP addition (see section Materials and 
Methods). As it is shown in the graph (Figure 4.8), the results improved with the 
variations carried out, but even in this way I was not able to reproduce the results 
claimed by Gertsch et al., in fact, at higher concentrations of compound, the 
displacement of [3H] CP55940 is efficient only for a 20%. 
4.4.2. BCP derivatives 
These BCP derivatives (Figure 4.9) are a follow-up of the functionalized amides 
derivatives obtained upon opening the BCP ring which were already investigated by 
Chicca et al. (Chicca et al. 2014). These new molecules were tested on the different 
target of the endocannabinoid system. 
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4.4.3. CB1 and CB2 receptor binding 
The binding assay was performed using both CB2 and CB1 membrane preparation 
obtained from CHO cells stably transfected with hCB1 or hCB2 receptors. The results 
showed that at the screening concentration of 3 µM, none of the compounds 
showed any significant binding to CB1 and CB2 receptors (Figure 4.10). 
 
 
Figure 4.10 CB1 and CB2 receptor binding for BCP derivatives at the screening concentration of 3 µM. 
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4.4.4. Enzymatic assay for MAGL, FAAH, ABHDs and COX-2 activity 
The activity of the main enzymes involved in the degradation of endocannabinoids 
was investigated initially testing the BCP derivatives at the screening concentration 
of 3 μM. Hit compounds were further tested in concentration-dependent 
experiments.  
4.4.4.1. MAGL activity 
Monoacylglycerol Lipase (MAGL) is the most efficient enzyme involved in the 
hydrolysis of 2-AG in the brain, being responsable for  approximately 85% of total 2-
AG hydrolysis (Blankman et al. 2009). As shown in Figure 4.11 none of the tested 
compounds induced a significant inhibition of 2-AG hydrolysis at 3 μM except of 
ALE16 which showed 30% of inhibition. 
 
 
 
Figure 4.11 MAGL inhibition induced by BCP derivatives. Derivatives tested at 3 µM. JZL-184 (1 µM) was used as 
positive control for MAGL inhibition. 
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To further characterized the inhibition activity of ALE 16, the assay was performed 
with different concentrations of the compound, as shown in Figure 4.12 the IC50 is 
15,3 µM. 
 
 
Figure 4.12 MAGL inhibition induced by different concentrations of ALE 16. JZL-184 (1 µM) was used as positive 
control for MAGL inhibition. 
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4.4.4.2. FAAH activity  
Fatty Acid Amide Hydrolase (FAAH) is a member of the serine hydrolase family of 
enzymes and it is the most involved enzyme in AEA hydrolysis. 
As reported in Figure 4.13, none of the tested compounds showed a significant 
inhibition at 3 µM. 
 
Figure 4.13 FAAH inhibition tested by BCP derivatives tested at 3 μM. URB-597 (100 nM) was used as positive 
control for FAAH inhibition. 
The assay above was performed using the standard FAAH assay conditions, but then 
was repeated with a variation: instead of pre-incubating the inhibitors before the 
enzymatic reaction started, the compounds were co-incubated with the enzyme 
substrate (see section Materials and Methods for details). The change in the assay 
execution was performed because all the BCP derivatives are amide (some are even 
ethanol-amide) so they have a chemical structure similar to AEA, the normal 
substrate of the enzyme. For that reason, they could also have been degraded by 
FAAH during the pre-incubation time without showing any effect after AEA addition. 
Instead, co-incubating the BCP derivatives with AEA for 10 min, could lead to a 
substrate competition and the consequent less hydrolysis of AEA by the enzyme. 
Even in this way, any of the tested compounds showed a significant enzyme 
inhibition at 3 µM (Figure 4.14). 
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Figure 4.14 FAAH inhibition tested by BCP derivatives tested at 3 μM with a variation in the incubation time. 
URB-597 (100 nM) was used as positive control for FAAH inhibition. 
4.4.4.3. ABHDs activity  
α, β hydrolase-6 and -12 (ABHD-6 and -12) also belong to the serine hydrolase 
family and they contribute by approximately 15% of the  2-AG total hydrolysis in the 
brain. As shown in Figure 4.15, none of the tested compounds significantly affected 
the activity of ABHD-6 at 3 µM. 
 
Figure 4.15 ABHD-6 inhibition induced by BCP derivatives tested at 3 μM. WWL70 (10 µM) was used as positive 
control for ABHD-6 inhibition. 
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The results of ABHD-12 inhibition at the screening concentration of 3 µM showed 
no effect for most of the compounds with the exception of ALE 18 and ALE 51, 
which inhibited only 20-30% of 2-AG hydrolysis (Figure 4.16). 
 
Figure 4.16 ABHD-12 inhibition induced by BCP derivatives tested at 3 μM. THL (or Orlistat) (20 µM) was used as 
positive control for ABHD-12 inhibition. 
4.4.4.4. COX-2 activity  
Beyond hydrolysis, endocannabinoids can be degraded via COX-2-mediated 
oxygenation. COX-2 is usually highly express during inflammatory processes and is 
able to covert the AA into PGH2 and start the biosynthetic pathway of prostaglandin 
production. It has been shown that (R)-enantiomers of some of the classic non-
steroidal anti-inflammatory drugs (NSAIDs), as naproxen, ibuprofen and 
flurbiprofen, which are considered inactive as COX inhibitors, because of their 
inability to inhibit AA oxygenation, actually bind to the enzyme and potently inhibit 
endocannabinoid oxygenation (Duggan et al. 2011). Here I tested the capability of 
BCP derivatives to inhibit COX-2 oxygenation of the classic substrate AA but also 2-
AG and AEA. For the first screening the compounds were tested at 10 μM using AA 
as a  substrate and as reported in Figure 4.17 , the most potent inhibitors were ALE 
33, ALE 12, ALE 62 and ALE 53 which bear an aromatic group in the amide side chain 
(a phenol with a methyl ether in position 2 for ALE 33 and ALE 53 and a catechol, for 
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ALE 12 and ALE62), while differing for the presence or not of the carbonyl group on 
the side chain connected to  the four-carbon-ring (Figure 4.9). 
 
 
Figure 4.17 COX-2 inhibition induced by BCP derivatives tested at 10 µM using AA as substrate. DuP-697 (5 μM) 
was used as positive controls for nonselective COX-2 inhibition. 
The assay was repeated at the screening concentration of 10 uM using 2-AG as 
substrate. For ALE 12, ALE 62, ALE 33 and AL 53 the concentration of 1 μM 
concentration was also tested (Figure 4.18). 
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Figure 4.18 Panel a: COX-2 inhibition induced by BCP derivatives tested at 10 µM using AA as substrate. Panel b: 
COX-2 inhibition induced by BCP derivatives tested at 10 µM using 2-AG as substrate. DuP-697 (5 μM) was used 
as positive controls for non selective COX-2 inhibition. 
ALE 62 and ALE 53, resulted the most potent inhibitors with a potential selectivity 
between AA and 2-AG oxygenation. Therefore, a full concentration curve was 
performed using AA, 2-AG and AEA as substrates (Figure 4.19). 
 
                       
 
Figure 4.19 Panel a: Concentration-dependent inhibition of COX-2 induced by ALE 62. Panel b: Concentration-
dependent inhibition of COX-2 induced by ALE 53. 
b 
a b 
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As shown in the table below, both compounds are slightly more selective for 
inhibiting AEA and 2-AG oxygenation compared to AA.  
 
 IC50 AA  IC50  2-AG  IC50 AEA  
ALE 62 531 nM 323 nM 362 nM 
ALE 53 661 nM 383 nM 375 nM 
 
Table 4.3 IC50 for AA, 2-AG and AEA for ALE 62 and ALE 53. 
 
For some of the classic NSAIDs, that were defined as COX-2 substrate-specific 
inhibitors (SSIs), the IC50 is in the nanomolar range (Duggan et al. 2011) as well as 
for the morpholine derivative of indomethacin (LM-4131) that was recently 
described as a COX-2 SSI (Hermanson et al. 2014). Comparing these data with the 
IC50 values of ALE 53 and ALE 62, we can say that they cannot be consider as 
selective and potent inhibitors of COX-2-mediated endocannabinoid oxygenation, 
but among the 12 BCP derivatives tested, they showed the best activity and their 
structures can be taken in account for further optimization in order to obtain a 
better inhibition of the enzyme. 
 
4.4.5. AEA uptake 
The endocannabinoid membrane transporter is responsible for the bidirectional 
trafficking of endocannabinoids across the plasma membrane (Chicca et al. 2012), 
even if the molecular entity has not yet been identified.  
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Figure 4.20 Inhibition of [
3
H] AEA uptake into U937 cells induced by BCP derivatives at 10 µM. UCM-707 and 
OMDM-2 (10 µM) were used as positive control. 
 
As shown in Figure 4.20, at the screening concentration of 10 µM, ALE 11 and ALE 
45 inhibited AEA uptake with a comparable efficiency as to the positive controls 
UCM707 and OMDM-2. Both ALE 11 and ALE 45 bear a similar chemical structure 
with an ethyl chlorine amide side chain (Figure 4.9), suggesting a role for the 
interaction with the endocannabinoid membrane transporter. A further assay was 
performed applying different concentrations of the compounds (100 μM, 30 μM, 10 
μM, 3 μM, 1 μM, 0.1μM, 10 nM). The AEA uptake inhibition concentration curve  
indicated IC50 value of 624
 µM and 487 µM for ALE11 and ALE45, respectively 
(Figure 4.21). 
75 
 
 
Figure 4.21 Concentration-dependent inhibition of [
3
H] AEA uptake into U937 cells induced by ALE 11 and ALE 
45. 
 
As reported by Chicca et al.’ , there is an independent interaction between FAAH 
inhibition and endocannabinoid transport inhibition, even if the AEA uptake and 
hydrolysis are indirectly related processes. This was also confirmed by ALE 11 and 
ALE 45 which inhibit AEA uptake being inactive on FAAH activity (Figure 4.13 and 
Figure 4.14). 
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